2264 related articles for article (PubMed ID: 20678680)
1. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
2. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
4. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
Blais L; Beauchesne MF; Forget A
Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647
[TBL] [Abstract][Full Text] [Related]
5. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
6. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.
Tunceli O; Williams SA; Kern DM; Elhefni H; Pethick N; Wessman C; Zhou S; Trudo F
J Allergy Clin Immunol Pract; 2014; 2(6):719-26. PubMed ID: 25439363
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
[TBL] [Abstract][Full Text] [Related]
10. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
11. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
12. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
13. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
15. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
[TBL] [Abstract][Full Text] [Related]
16. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
17. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
Hagiwara M; Delea TE; Stanford RH
J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
[TBL] [Abstract][Full Text] [Related]
19. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
20. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
Simoni-Wastila L; Yang HW; Blanchette CM; Zhao L; Qian J; Dalal AA
Curr Med Res Opin; 2009 Nov; 25(11):2729-35. PubMed ID: 19778165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
